fludeoxyglucose (18f)-curium 185mbq/ml solution for injection
curium international boulevard bischoffsheim 39 boîte 4 1000 bruxelles , belgium - fludeoxyglucose - solution for injection - fludeoxyglucose 185 mbq/ml - diagnostic radiopharmaceuticals
efdege 1.0 gbq/ml, solution for injection (11ml vial)
iason gmbh feldkirchner str. 4, a-8054 graz, austria - fludeoxyglucose - solution for injection - fludeoxyglucose 1 gigabecquerel/millilitre - diagnostic radiopharmaceuticals
efdege 1.0 gbq/ml, solution for injection (25ml vial)
iason gmbh feldkirchner str. 4, a-8054 graz, austria - fludeoxyglucose - solution for injection - fludeoxyglucose 1 gigabecquerel/millilitre - diagnostic radiopharmaceuticals
ertracer fludeoxyglucose (18f) injection, solution 1-13 gbq/ml solution for injection
m2i limited - fludeoxyglucose (18f) - solution for injection - 1-13 gbq/ml
fludeoxyglucose f 18 injection, solution
petnet solutions, inc. - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 200 mci in 1 ml - fludeoxyglucose f 18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose
ertracer solution for injection
curium pharma ireland limited - fludeoxyglucose [18f] - solution for injection - 110-10,000 megabecquerel(s)/millilitre - other diagnostic radiopharmaceuticals for tumour detection; fludeoxyglucose (18f)
fludeoxyglucose (18f) rtm 200 mbq/ml inj. sol. i.v. vial
radboud translational medicine b.v. - fludeoxyglucose (18 f) 200 mbq/ml - solution for injection - 200 mbq/ml - fludeoxyglucose (f-18) 200 mbq/ml - fludeoxyglucose (18f)
fludeoxyglucose f18 injection, solution
the methodist hospital research institute - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 0.3 ci in 1 ml - fludeoxyglucose f18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection usp crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiatio
fludeoxyglucose f-18 injection, solution
trustees of the university of pennsylvania - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 200 mci in 1 ml - fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. pregnancy category c. animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in
fludeoxyglucose f-18 injection, solution
precision nuclear, llc - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d